Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epratuzumab + R-CHOP in Previously Untreated DLBCL
NCT00301821Phase 2Completed
- Sponsor
- Cancer and Leukemia Group B
- Start
- Jan 2006
- Primary completion
- Oct 2008
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of epratuzumab in diffuse large B-cell lymphoma (DLBCL), sponsored by Cancer and Leukemia Group B. Started Jan 2006; status: completed.
02
Drugs
epratuzumab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT00301821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00301821.